Abstract
Human microbiota has gained significant interest in the prevention and treatment of cancer. Synbiotics are profound examples of how microbiota can be manipulated for therapeutic purpose and their importance in the therapeutic management of cancer. Lung cancer is considered to be the second largest death-causing cancer worldwide. One-third of the cancer pathology can be prevented by maintaining a healthy nutritious diet and tailor-made supplements of probiotics and prebiotics. Synbiotics are the combination of both prebiotics and probiotics, whose synergistic effect results in an adverse change in gut microbial flora. The microbial content in the gastrointestinal tract of lung cancer patients differs hugely from the normal healthy person. Based on the gut-lung axis, it has been proposed that the imbalance in the gut microbial flora may cause lung cancer. Reduced composition of Firmicutes and Bacteroides leads to lung cancer. These microbes can serve as a biomarker for the detection of lung cancer. Gut microbial flora decreases further during antibiotic-associated chemotherapy. Hence, administration of appropriate synbiotics could either restore these depleted microorganisms or introduce new microorganisms to our gut which could enhance anti-cancer activity and confer health benefits on the host. Ultimately, understanding the gut-lung axis and the influence of the microbiome involved in lung cancer may help decide the therapeutic interventions. This chapter summarizes the types, causative agents, and treatment strategies of lung cancer, an overview of synbiosis highlighting the gut microbiome, with a prime focus on synbiosis and dysbiosis of lung cancer patients. The onco-suppressive effects of synbiotics by modulating the immune responses and maintaining the intestinal barrier function have been discussed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ale EC, Binetti AG (2021) Role of probiotics, prebiotics, and synbiotics in the elderly: insights into their applications. Front Microbiol 12:631254. https://doi.org/10.3389/fmicb.2021.631254
Bingula R, Filaire M, Radosevic-robin N, Bey M, Berthon J, Bernalier-donadille A, Vasson M, Filaire E (2017) Desired turbulence? Gut-lung Axis, immunity, and lung cancer. J Oncol 2017:5035371
Cerezuela R, Meseguer J, Esteban MA (2011) Current knowledge in synbiotic use for fish aquaculture: a review. J Aquac Res Dev 1:1–7. https://doi.org/10.4172/2155-9546.S1-008
De Maria YNLF, Barbosa DA, Menegidio FB, Santos KBNH, Humberto AC, Alencar VC, Silva JFS, De Oliveira RC, Batista ML, Nunes LR, Jabes DL (2021) Analysis of mouse fecal dysbiosis, during the development of cachexia, induced by transplantation with Lewis lung carcinoma cells. Microbiology 167(10). https://doi.org/10.1099/mic.0.001088
Escalera E, Bellido L, del Barco E, Cigarral B, Barrios B, Casado D, Claros J, Figuero L, Olivares A, Terán E, López A, Cruz JJ (2021) Small cell lung cancer. Medicine 13(25). https://doi.org/10.1016/j.med.2021.02.001
Gui QF, Lu HF, Zhang CX, Xu ZR, Yang YM (2015) Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. Genet Mol Res 14(2):5642–5651. https://doi.org/10.4238/2015.May.25.16
Gui Q et al (2020) The association between gut butyrate-producing bacteria and non-small-cell lung cancer. J Clin Lab Anal 34:E23318
Liu F, Li J, Guan Y, Lou Y, Chen H, Xu M, Deng D, Chen J, Ni B, Zhao L, Li H, Sang H, Cai X (2019) Dysbiosis of the gut microbiome is associated with tumor biomarkers in lung cancer. Int J Biol Sci 15(11):2381–2392. https://doi.org/10.7150/ijbs.35980
Liu NN, Ma Q, Ge Y, Yi CX, Wei LQ, Tan JC, Chu Q, Li JQ, Zhang P, Wang H (2020) Microbiome dysbiosis in lung cancer: from composition to therapy. NPJ Precis Oncol 4(1). https://doi.org/10.1038/s41698-020-00138-z
Liu X, Cheng Y, Zang D, Zhang M, Li X, Liu D, Gao B, Zhou H, Sun J, Han X, Lin M, Chen J (2021) The role of gut microbiota in lung cancer: from carcinogenesis to immunotherapy. Front Oncol 11:1–13. https://doi.org/10.3389/fonc.2021.720842
López A, Escalera E, del Barco E, Bellido L, Cigarral B, Barrios B, Casado D, Claros J, Figuero L, Olivares A, Terán E, Cruz JJ (2021) Non-small cell lung cancer. Medicine 13(25). https://doi.org/10.1016/j.med.2021.02.002
Lukeman JM (2015) What is lung cancer? Perspectives in Lung Cancer:30–40. https://doi.org/10.1159/000400400
Minna JD, Roth JA, Gazdar AF (2002) Focus on lung cancer. Cancer Cell 1:49–52
Mustafa M, Jamalulazizi AR, Iiizam EL, Nazirah A, Abbas SA (2016) Lung cancer: risk factors, management, and prognosis lung cancer : risk factors, management, and prognosis. IOSR J Dent Med Sci. https://doi.org/10.9790/0853-15100494101
Pandey KR, Naik SR, Vakil BV (2015) Probiotics, prebiotics and synbiotics–a review. J Food Sci Technol 52(12):7577–7587. https://doi.org/10.1007/s13197-015-1921-1
Sagar S, Folkerts G, Garssen J (2015) Prebiotics, probiotics, and synbiotics for the management of respiratory disease. In: Bagchi D, Preuss HG, Swaroop A (eds) Nutraceuticals and functional foods in human health and disease prevention. https://doi.org/10.1201/b19308
Scott AJ, Merrifield CA, Younes JA, Pekelharing EP (2018) Pre-, pro- and synbiotics in cancer prevention and treatment—a review of basic and clinical research. Ecancermedicalscience 12:1–11. https://doi.org/10.3332/ecancer.2018.869
Spiro SG, Silvestri GA (2005) Centennial review one hundred years of lung cancer. Am J Respir Crit Care Med 172:523–529. https://doi.org/10.1164/rccm.200504-531OE
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K, Scott KP, Holscher HD, Azad MB, Delzenne NM, Sanders ME (2020) The international scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol 17(11):687–701. https://doi.org/10.1038/s41575-020-0344-2
Travis WD (2011) Pathology of lung cancer. Clin Chest Med 32(4):669–692. https://doi.org/10.1016/j.ccm.2011.08.005
Vyas U, Ranganathan N (2012) Probiotics, prebiotics, and synbiotics: gut and beyond. Gastroenterol Res Pract 2012:872716. https://doi.org/10.1155/2012/872716
Zhou A et al (2022) Gut microbiota: the emerging link to lung homeostasis and disease. J Bacteriol 203(4):e00454–e00420
Acknowledgment
The authors express their gratitude to SASTRA-Deemed-to-be-University, Tamil Nadu, India for infrastructure and financial support. Authors also extend their appreciation for the contribution of Biopharmaceutical research lab members, SASTRA-Deemed-to-be-University.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
Diwahar Prakash: Writing—Original Draft, Writing—Review and Editing Collection of data; Suresh Krishna Venkataramanan: Writing—Original Draft, Writing—Review and Editing, Collection of data; Gayathri G: Writing—Original Draft, Review and Editing; Shibi Muralidar: Writing—Original Draft, Review, and Editing; Senthil Visaga Ambi: Conceptualization, Visualization, Supervision, and Writing—Review and Editing.
Conflict of Interest
The authors declare no conflict of interest.
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Prakash, D., Venkataramanan, S.K., Gopal, G., Muralidar, S., Ambi, S.V. (2023). Synbiotics in Lung Cancer. In: Mishra, N., Bhatt, S., Paudel, K.R., M Hansbro, P., Dua, K. (eds) Synbiotics for the Management of Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-19-7550-9_9
Download citation
DOI: https://doi.org/10.1007/978-981-19-7550-9_9
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-7549-3
Online ISBN: 978-981-19-7550-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)